Lack of a clinically relevant effect of an antacid on the pharmacokinetics of lersivirine

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 5, 2010, Pages 2209-2211

  Vourvahis, M ^a   Banerjee, S ^a   Labadie, R ^a   Gore, D ^b   Mayer, H ^a,c  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c EMD SERONO INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; ANTACID AGENT; ANTIVIRUS AGENT; LERSIVIRINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG EFFECT; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GEOMETRY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NORMAL HUMAN; PH; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; VOMITING;

ADULT; ALUMINUM HYDROXIDE; ANTACIDS; AREA UNDER CURVE; CROSS-OVER STUDIES; DRUG COMBINATIONS; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HUMANS; MAGNESIUM HYDROXIDE; MALE; MIDDLE AGED; NITRILES; PYRAZOLES; REFERENCE VALUES; REVERSE TRANSCRIPTASE INHIBITORS; YOUNG ADULT;

EID: 77951232416     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01110-09     Document Type: Article

References (9)

1. Crauwels, H. M., R. P. G. van Heeswijk, D. Kestens, M. Stevens, A. Buelens, K. Boven, and R. M. W. Hoetelmans. 2008. The pharmacokinetic (PK) interaction between omeprazole and TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI). J. Int. AIDS Soc. 11(Suppl. 1):239.
2. Davis, J., E. Asken, H. Stafford, F. Hackman, G. Weissgerber, and T. Jenkins. 2007. Safety, toleration and pharmacokinetics of single and multiple oral doses of UK-453,061, a novel NNRTI, in healthy male subjects, abstr. WEPEA 109. Abstr. 4th IAS Conf. HIV Pathog., Treat., Prev.
3. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. 2008. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, p. 1-139. Department of Health and Human Services, Washington, DC.
4. Fatkenheuer, G., S. Staszewski, A. Plettenberg, F. Hackman, G. Layton, L. McFadyen, J. Davis, and T. Jenkins. 2009. Activity, pharmacokinetics, and safety of lersivirine (UK-453,061), a next-generation NNRTI, during 7-day monotherapy in HIV-1-infected patients. AIDS 23:2115-2122.
5. Mori, J., R. Corbau, D. Lewis, S. Ellery, H. Mayer, and M. Perros. 2008. In vitro characterization of UK-453,061, a non-nucleoside reverse transcriptase inhibitor, abstr. F-134. Abstr. 15th Conf. Retrovir. Opportun. Infect., Boston, MA, 3 to 6 February 2008.
6. Van Heeswijk, R., R. Hoetelmans, D. Kestens, M. Stevens, M. Peeters, P. Williams, B. Woodfall, and K. Boven. 2007. The pharmacokinetic (PK) interaction between famotidine and TMC278, a next generation non-nucleoside reverse transcriptase inhibitor (NNRTI), in HIV-negative subjects, abstr. TUPDB01. Abstr. 4th IAS Conf. HIV Pathog., Treat., Prev.
7. van Lunzen, J., H. Liess, K. Arasteh, R. Walli, B. Daut, and D. Schurmann. 2007. Concomitant use of gastric acid-reducing agents is frequent among HIV-1-infected patients receiving protease inhibitor-based highly active anti-retroviral therapy. HIV Med. 8:220-225.
8. Vourvahis, M., M. Gleave, A. Nedderman, I. Gardner, and R. LaBadie. 2009. Mass balance of lersivirine (UK-453,061), a next-generation NNRTI, following administration of [14C] lersivirine to healthy subjects, poster P61. Abstr. 10th Int. Workshop Clin. Pharmacol. HIV Ther., Amsterdam, Netherlands, 15 to 17 April 2009.
9. Yeh, L., S. Ramael, S. Comhaire, V. Hingorani, K. Manhard, M. Nguyen, K. Tieu, and B. Quart. 2009. Safety and pharmacokinetics of ascending single oral doses of RDEA806, a novel HIV non-nucleoside reverse transcriptase inhibitor, in healthy subjects, poster A-1429. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL, 17 to 20 September 2009.